How pharma can optimize for right-the-first-time drug manufacturing and sustainability

[Image by Gerd Altmann from Pixabay

The pharmaceutical industry is gradually going green. More pharma companies are embracing sustainability metrics and striving to reduce corporate emissions and their footprint.

More than 25% of major pharma and biopharma companies are committed to reaching net-zero carbon emissions by 2050. Many are also committed to ensuring equal access to medicine for the 2 billion people worldwide that are currently underserved and rely on the United Nations Sustainable Development Goals (UN SDGs). Those initiatives are designed to improve human and planet health while helping achieve sustainable business practices.

Working toward a prosperous and equitable future while building healthy communities can directly support current and future business operations for pharma and biopharma organizations. These companies have concluded there does not need to be a choice between being envi…

Read more
  • 0

Digital transformation will give scientists their time back and speed the development pipeline

Image courtesy of IDBS

The pandemic exposed the innovation divide between the digitally transformed and those that lagged. Strict regulation made life sciences and bio/pharma organizations hesitant to modernize too quickly away from proven legacy methods and technologies, resulting in varying levels of digital transformation. But since the pandemic, organizations now recognize the necessity of digitalization and smart automation to accelerate research and drug development.

Freeing up and transforming researchers’ time

Companies that haven’t embraced the digital revolution, including digital (process) automation, tend to burden scientists with repetitive, manual work — like pipetting and recordkeeping. Digitally automated systems perform such tasks in more digitalized companies. Companies embracing future-facing technologies are investing in automation and digitalization, allowing for virtual remote access to…

Read more
  • 0